EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications

Luca Bonanni, Ada Cutolo, Nicola Ferri

Cardiovascular Drugs and Therapy · 2026-08 · 40 (4) · 1629-1635

DOI: 10.1007/s10557-026-07855-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 18.02.2026. Verfasst von Luca Bonanni und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Ospedale dell'Angelo, Venice, Italy. luca.bonanni@aulss3.veneto.it. Hauptthemen laut MEDLINE: Dyslipidemias, Hypolipidemic Agents, Cholesterol, LDL. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 2025 ESC/EAS Dyslipidaemia Focused Update provides a targeted revision of the 2019 guidelines, integrating newly available evidence with the potential to influence clinical decision-making before the next full update. While LDL-C treatment targets remain unchanged, the document reshapes how they should be achieved, emphasizing faster therapeutic intensification, broader use of combination therapy and improved risk stratification with SCORE2/SCORE2-OP, lipoprotein(a) [Lp(a)] and coronary artery calcium (CAC) scoring. New evidence supporting bempedoic acid, inclisiran and evinacumab expands the therapeutic armamentarium, particularly for patients at high, very high and extreme cardiovascular risk or those with statin intolerance. In the acute coronary syndrome (ACS) setting, the update reinforces a more proactive, early-intensification approach. Overall, the Focused Update refines the operational framework of LDL-C management, promoting earlier, more personalized and more sustained lipid lowering to reduce cumulative atherosclerotic exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasHypolipidemic AgentsCholesterol, LDLHumansBiomarkersRisk AssessmentRisk FactorsHeart Disease Risk Factors

Stichwörter der Autor:innen

Cardiovascular preventionDyslipidaemia ManagementLDL Cholesterol TargetsESC/EAS GuidelinesGuideline UpdateLipid-Lowering Therapy

Substanzen

Hypolipidemic AgentsCholesterol, LDLBiomarkers

Autor:innen und Institutionen

  • Department of Medicine, Ospedale dell'Angelo, Venice, Italy. luca.bonanni@aulss3.veneto.it.
  • Department of Medicine, University of Padova, Padova, Italy. luca.bonanni@aulss3.veneto.it.
  • Department of Medicine, Ospedale dell'Angelo, Venice, Italy.
  • Department of Cardiology, Ospedale dell'Angelo, Venice, Italy.
  • Department of Medicine, University of Padova, Padova, Italy.

Zitieren

APA

Bonanni, L., Cutolo, A., & Ferri, N. (2026). The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications. Cardiovascular Drugs and Therapy, 40(4), 1629-1635. https://doi.org/10.1007/s10557-026-07855-w

Vancouver

Bonanni L, Cutolo A, Ferri N. The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications. Cardiovascular Drugs and Therapy. 2026;40(4):1629-1635. doi:10.1007/s10557-026-07855-w

BibTeX
@article{Bonanni2026,
  author = {Bonanni, Luca and Cutolo, Ada and Ferri, Nicola},
  title = {The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2026},
  volume = {40},
  number = {4},
  pages = {1629--1635},
  doi = {10.1007/s10557-026-07855-w}
}
Kostenlos starten →